« Back to Vicor Press Releases
Vicor Technologies' Chief Medical Officer Interviewed On National Public Radio; Discusses Technology For Measuring Heart Rate Variability And Sudden Cardiac Death
Patented, Proprietary PD2i Analyzer Now Awaiting FDA Marketing Clearance
BOCA RATON, FL — November 10, 2008 –– Vicor Technologies, Inc. (OTCBB: VCRT) announced that the interview with its Chief Medical Officer, Daniel N. Weiss, M.D., FACC, on "Cutting Edge with Anita" is available on the Company's website: www.vicortech.com. Vicor is a biotechnology company that has developed the PD2i, a patented, proprietary algorithm and is now awaiting FDA 510 (k) clearance for its first product, the PD2i Analyzer that measures heart rate variability. The Company is also involved in clinical trials for 510(k) clearance for use of the PD2i algorithm in a) risk stratifying combat and civilian trauma victims (PD2i VS) and b) identifying patients at risk of suffering Sudden Cardiac Death (PD2i CA).
Dr. Weiss spoke with host Anita Finley about Sudden Cardiac Death (SCD) and Vicor's PD2i Cardiac Analyzer. "Cutting Edge with Anita" features five interviews with and about persons and places of interest around the globe. The program is produced and broadcast over National Public Radio by WXEL in West Palm Beach, Florida.
"Following Tim Russert's untimely passing, there is a tremendous surge of interest in learning about Sudden Cardiac Death," stated David H. Fater, Vicor's President and CEO. "With as many as 500,000 deaths annually, Sudden Cardiac Death is among the leading causes of death in the United States. Vicor is one of two companies with a technology for identifying those at risk of suffering Sudden Cardiac Death within a 6-12 month time frame. We're gratified to be among those helping the public gain a better understanding of the causes of and methods for identifying those at risk of Sudden Cardiac Death," Mr. Fater concluded.
Dr. Weiss has extensive experience in the practice of cardiology and electrophysiology. In addition to serving as Vicor's Chief Medical Officer, Dr. Weiss is the former Medical Director of the electrophysiology laboratory of the Boca Raton Community Hospital in Boca Raton, FL. and a former partner with Florida Arrythmia Consultants. He has served as a consultant to medical device manufacturers such as Medtronic, St. Jude Medical and Guidant. He also served as a clinical investigator in the two most important clinical trials involving the study of ICDs and SCD, MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial) and SCD HeFT (Sudden Cardiac Death Heart Failure Trial). Dr. Weiss earned his MD (with Distinction in Research) from the Mount Sinai School of Medicine in New York, from which he also received the Nathan A. Setz Award for Research in Cardiovascular and Renal Disease. He holds a BSE, cum laude, in Electrical Engineering and Computer Science from Princeton University.
About Vicor Technologies, Inc.
Vicor Technologies, Inc. (OTCBB: VCRT) ("the Company") is a development-stage biotechnology company dedicated to the development of breakthrough diagnostic products. The Company's diagnostic technology, currently being commercialized, is based on a patented, proprietary algorithm, PD2i. The PD2i algorithm and operational software facilitates the ability to accurately risk stratify a target population to predict future pathological events.
Vicor's PD2i Analyzer, PD2i Vital Sign (PD2i VS), and PD2i Cardiac Analyzer (PD2i CA) employ the firm's patented, proprietary point correlation dimension algorithm (PD2i), a deterministic, non-linear analytic measure that accurately measures heart rate variability (HRV) through the analysis of electrocardiographic data. The clinical significance of HRV and use of the PD2i Analyzer as a diagnostic tool is physician-determined. Vicor expects to receive FDA clearance for the PD2i Analyzer in 4Q08. Such clearance will enable Vicor to market and distribute the PD2i Analyzer for use while completing clinical trials and the FDA clearance process for its PD2i VS and PD2i CA.
The PD2i VS enables risk stratification of trauma severity to identify those in need of immediate Life Saving Intervention and improve emergency triage efforts. The PD2i VS is currently in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research.
The PD2i CA identifies patients at risk of suffering a fatal arrhythmic event or Sudden Cardiac Death within 6-12 months. The PD2i CA is currently involved in a multi-site, multi-year trial (the VITAL Trial) being conducted by the Harvard Clinical Research Institute.
Vicor anticipates developing additional applications using the PD2i algorithm to enable early detection of Alzheimer's Disease, and a variety of other disorders and diseases.
More information about Vicor may be found at www.vicortech.com.
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: the results of clinical studies analyzing the effectiveness of the PD2i Analyzer, our ability to obtain FDA clearance of the PD2i Cardiac Analyzer for military and civilian applications, our ability to continue to receive financing sufficient to complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory clearance for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.